Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
While cross-reactivity between tirzepatide and other GLP-1 receptor agonists (such as semaglutide, dulaglutide, or liraglutide) is theoretically possible, the evidence establishing such cross-sensitivity is limited
The proportion of participants achieving at least 10% weight loss was 70.9% with semaglutide versus 25.6% with liraglutide
Purpose-built for physicians Out-of-pocket costs for GLP-1s rising for Medicare Part D beneficiaries Key takeaways: Medicare Part D beneficiaries had an increase in out-of-pocket spending for GLP-1s approved for diabetes in 2025
doi: 10.3390/jof3010014 68 PoonY.HuiM
Additionally, individual differences in how patients respond to GLP-1 therapy may influence side effect profiles
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific statement
US$ 22.66
US$ 28.27
US$ 26.28
US$ 20.42
US$ 23.85
US$ 27.65
US$ 27.23
US$ 23.19
US$ 22.60
US$ 24.91
